ClinicalTrials.Veeva

Menu
R

Retinal Diagnostic Center | Campbell, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Faricimab
Lampalizumab
APL-2
Ranibizumab
Aflibercept
Triamcinolone Acetonide
Strontium90 Beta
RO7446603
Bevacizumab
Pemafibrate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 35 total trials
Locations recently updated

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema (THAMES)

This study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME)....

Enrolling
Diabetic Macular Edema
Drug: Faricimab
Drug: Aflibercept

This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treat...

Active, not recruiting
Diabetic Macular Edema
Drug: Faricimab

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: PEGCETACOPLAN (APL-2)

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling
Choroidal Neovascularization
Wet Age-related Macular Degeneration
Genetic: ABBV-RGX-314
Biological: Ranibizumab (LUCENTIS®)

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling
Wet Age-related Macular Degeneration
WetAMD
Biological: Aflibercept (EYLEA®)
Genetic: ABBV-RGX-314 Dose 2

ABBV-RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of Diabetic Retinopathy (DR) with and without...

Enrolling
Diabetic Retinopathy (DR)
Center-Involved Diabetic Macular Edema (CI-DME)
Genetic: ABBV-RGX-314 Dose 4
Biological: Aflibercept

Trial sponsors

Roche logo
Jaeb Center for Health Research logo
Genentech logo
AbbVie logo
A
Pfizer logo
T
Allergan logo
Astellas logo
C

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems